Benzinga | Dec 28, 2020 09:57AM EST

Canaccord Genuity Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $57

Canaccord Genuity maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $70 to $57.